{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"15.3","value":"10.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"PD-L1 < 1%"},{"categories":[{"measurements":[{"comment":"Not reached due to insufficient number of events","groupId":"OG000","lowerLimit":"4.0","upperLimit":"NA","value":"16.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"PD-L1 >= 1%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"description":"PFS was measured from time of enrollment until the first date of recurrent or progressive disease, or death due to any cause. Expression level of PD-L1 was assessed in tumor biopsy samples. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).","id":"OG000","title":"Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W"}],"paramType":"MEDIAN","populationDescription":"The biomarker analysis set (BAS) included all participants in the FAS who had samples evaluable for PD-L1 assay. Here, 'Overall number of participants analyzed' signifies participants who are evaluable for this outcome measure and \"Number analyzed\" is the number of participants in each row category. Only Group 6 was planned for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 65 months (treatment period + follow-up including survival follow-up)","title":"PFS by Independent Central Review for Participants With Evaluable PD-L1 Assays","type":"SECONDARY","unitOfMeasure":"months"}